Nilesh Gupta, managing director of Lupin Pharmaceuticals, warned a potential border tax in the U.S. could be highly disruptive for Indian drug manufacturing companies, reports BloombergQuint.
Lupin supplies the second largest amount of generic drugs to the U.S. From October to December of last year, the U.S. market made up 49.4 percent of Lupin's sales.
While President Donald Trump's proposed border adjustment tax aims to encourage more manufacturing in the U.S. by implementing a tariff on imported goods, Mr. Gupta said the tax could adversely affect supply chains and cause higher costs for Indian drugmakers importing generic drugs into the U.S.
The drugmaker plans to launch 25 new products in the U.S. in fiscal year 2018.
More articles on supply chain:
Why pharmacists can't speak up when they know customers are overpaying for drugs
LCMC Health partners with The Resource Group for supply chain services
Pharma leaders, healthcare experts advocate value-based payments for drugs